文献速递肝肾功能剂量调整特殊人群用药治疗药物监测与药物基因组学

危重症相关药代动力学改变

Pharmacokinetic Alterations Associated with Critical Illness.
PubMed 文献 · Clin Pharmacokinet · 2023-02-02

该综述探讨危重症患者因血流动力学、代谢和生化紊乱导致的药代动力学改变,涉及药物蛋白结合、分布容积、口服吸收、肝肠代谢和肾清除等变化。复苏策略和血管活性药物可产生相反效应,器官支持治疗增加变异性。目标导向治疗和TDM是目前安全用药的最佳选择。

要点

  • 危重症改变药物蛋白结合、离子化和分布容积。
  • 复苏和血管活性药物可增加肝肾血流和药物清除。
  • 目标导向治疗和TDM是危重症安全用药最佳选择。

核心结论

  • 危重症多种竞争因素使药物反应难以预测,目标导向治疗和TDM是目前安全用药的最佳选择。

研究设计与样本

  • 综述,总结危重症相关药代动力学改变的现有证据。

主要发现

  • 危重症导致药物蛋白结合、离子化和分布容积改变,并降低口服吸收、肠道和肝脏代谢及肾清除。
  • 复苏策略和血管活性药物可导致高动力状态,增加脑、心、肾、肝血流,进而增加肝代谢和肾排泄。
  • 代谢是药物清除的主要机制,受患者特异性、治疗特异性和疾病特异性因素影响。
  • 机械通气、肾脏替代治疗和体外膜氧合等器官支持可增加药代动力学的个体间和个体内变异。

临床怎么用

  • 根据治疗目标进行药物治疗调整,并开展治疗药物监测以保障危重症患者安全。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Haemodynamic, metabolic, and biochemical derangements in critically ill patients affect drug pharmacokinetics and pharmacodynamics making dose optimisation particularly challenging. Appropriate therapeutic dosing depends on the knowledge of the physiologic changes caused by the patient's comorbidities, underlying disease, resuscitation strategies, and polypharmacy. Critical illness will result in altered drug protein binding, ionisation, and volume of distribution; it will also decrease oral drug absorption, intestinal and hepatic metabolism, and renal clearance. In contrast, the resuscitation strategies and the use of vasoactive drugs may oppose these effects by leading to a hyperdynamic state that will increase blood flow towards the major organs including the brain, heart, kidneys, and liver, with the subsequent increase of drug hepatic metabolism and renal excretion. Metabolism is the main mechanism for drug clearance and is one of the main pharmacokinetic processes affected; it is influenced by patient-specific factors, such as comorbidities and genetics; therapeutic-specific factors, including drug characteristics and interactions; and disease-specific factors, like organ dysfunction. Moreover, organ support such as mechanical ventilation, renal replacement therapy, and extracorporeal membrane oxygenation may contribute to both inter- and intra-patient variability of drug pharmacokinetics. The combination of these competing factors makes it difficult to predict drug response in critically ill patients. Pharmacotherapy targeted to therapeutic goals and therapeutic drug monitoring is currently the best option for the safe care of the critically ill. The aim of this paper is to review the alterations in drug pharmacokinetics associated with critical illness and to summarise the available evidence.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Morales Castro D, Dresser L, Granton J, et al. Pharmacokinetic Alterations Associated with Critical Illness. Clin Pharmacokinet. 2023. PMID: 36732476. doi:10.1007/s40262-023-01213-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。